Tamoxifen retinopathy: a case report
© Wang et al. 2015
Received: 18 August 2015
Accepted: 18 August 2015
Published: 17 September 2015
To present a case of tamoxifen retinopathy on a 57-year-old woman.
An observational case.
A review of history, clinical examination, and findings on Spectral-domain Optical Coherence Tomography (SD-OCT), fluorescein angiogram (FA) and electro-oculogram (EOG) was conducted.
A 57-year old female patient, who had been treated with oral tamoxifen after mastectomy due to breast cancer, had profound visual impairment in both eyes. Disruption of the ellipsoid zone and interdigitation zone which represent photoreceptor damage as well as macular thinning was revealed on SD-OCT in both eyes. Bilateral retinal pigmented epithelium (RPE) function compromised was indicated by reduced Arden ratio in EOG.
Tamoxifen-induced retinopathy could be detected by SD-OCT and EOG. As it is irreversible, patients who are given tamoxifen need regular ophthalmic consultation, including SD-OCT and EOG before and during the treatment in order to early detect and avoid further retinal damage.
Tamoxifen is an oral estrogen antagonist drug, which is an adjuvant treatment of breast cancer when used in low doses (Early Breast Cancer Trialists’ Collaborative Group 2005; US Food and Drug Administration, Center for Drug Evaluation and Research 2006). Toxic effects of tamoxifen on ocular were first described in 1978 and the reported incidence of ocular side effects of tamoxifen ranges from 0.9 to 11 %, including keratopathy, cataract, optic neuritis, crystalline retinopathy with or without macular edema, and pseudocysticfoveal cavitation (Kaiser-Kupfer and Lippman 1978; Salomao et al. 2007; Doshi et al. 2014).
The current standard treatment with Tamoxifen for breast cancer is 5 consecutive years, however the global Adjuvant Tamoxifen: Longer against Shorter (ATLAS) trial has recently showed that 10 years of treatment reduced the risk of recurrence and mortality of breast cancer (Davies et al. 2013). Thus, a longer treatment of tamoxifen may be adopted and its toxicity on eyes should be in more concerned. We present a case of tamoxifen retinopathy detected mainly by spectral-domain optical coherence tomography (SD-OCT) and electro-oculogram (EOG).
A 57-year-old female presented to our clinic complaining of gradual progressive diminution of vision for 9 years and distortion for 3 months in the left eye. Her best visual acuity had been 20/20 bilaterally in the past. Her past medical history included hypertension, diabetes, hyperlipidemia and a radical mastectomy of the right breast for cancer 13 years ago and subsequent initiation of oral tamoxifen 20 mg per day for 5 year with cumulative dose of 36.5 g. Chemotherapy with paclitaxel and epirubin for breast cancer had been used for 6 months after mastectomy. Current medications were levamlodipinebesylate, olmesartan, acarbose, Novolin 30R, probucol and simvastatin.
The patient had once received chemotherapy with paclitaxel and epirubin for 6 months and side effects of these drugs on retina should be considered. It had been reported that paclitaxel could cause macular edema and transient blurred vision with photopia while epirubicin mainly affected the stability of tear film (Li et al. 2014; Seidman et al. 1994; Karamitsos et al. 2013). No retinopathy represented in this case had been reported in patients on the medication of paclitaxel or epirubicin.
None of the patient’s current medication had been reported to be toxic towards retina. So it is highly probable that the patient’s retinopathy was blamed to tamoxifen. Hence, tamoxifen retinopathy and moderate non-proliferated diabetic retinopathy was diagnosed. Oral vitamin C 1 g QD was prescribed.
In follow-up after 3 months by telephone, the patient denied any visual changes.
Tamoxifen retinopathy is characterized by bilateral presence of crystalline deposits with or without macular edema (Drenser et al. 2006). Recently, with developments of retinal imaging such as SD-OCT, more and more manifestations of tamoxifen retinopathy has been reported including cavitation in the macular (Doshi et al. 2014).
In this case, SD-OCT revealed diffused disruption of the ellipsoid zone and interdigitation zone in the left eye, which was correspond to the complaint of blurred vision with distortion in the left eye while no obvious distortion was reported in the right eye. The atrophy of the retinal tissue disclosed by SD-OCT was similar to the previous case reports of tamoxifen-induce retinopathy which presented as cavitation in the macular (Doshi et al. 2014).
EOG is a sensitive method to detect the function of retinal pigmented epithelium (RPE), which plays a critical role in the homeostasis of photoreceptors, phagocytizing the outer segment tips of photoreceptors. It had been found to reveal differences in patients with tamoxifen retinopathy, but it was not statistically significant, possibly owing to limited number of cases (Kuchenbecker et al. 2001). However, our patient’s EOG showed reduced Arden radio, indicating the impaired function of the RPE and explaining why the patient’s disease was still progressing even tamoxifen had been stopped for 8 years. In vitro study had revealed that tamoxifen has potential toxicity on RPE and photoreceptors, as well as alternating Muller cell’s function (Cho et al. 2012; Kim et al. 2014).
A longer treatment of tamoxifen therapy may be adopted according to ATLAS trial (Davies et al. 2013). Meanwhile more attention should be paid on whether it would increase the risk of developing tamoxifen ocular toxicity. Unlike corneal toxicity that has been reported to be reversible if tamoxifen therapy is stopped (Zinchuk et al. 2006), retinopathy is irreversible (Doshi et al. 2014; Nair et al. 2012). So it is of great value to detect signs of tamoxifen-induced retinopathy. As SD-OCT and EOG are sensitive to detect, from anatomical and functional aspects respectively, we suggest patients treated with tamoxifen taking a baseline ophthalmic examination before therapy initiation and periodic evaluations including SD-OCT and EOG during the treatment.
XL managed the case, and approved the final version of the manuscript. HM edited the manuscript. LW prepared and wrote the manuscript. All authors read and approved the final manuscript.
Compliance with ethical guidelines
Competing interests The authors declare that they have no competing interests.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
- Cho KS, Yoon YH, Choi JA, Lee SJ, Koh JY (2012) Induction of autophagy and cell death by tamoxifen in cultured retinal pigment epithelial and photoreceptor cells. Invest Ophthalmol Vis Sci 53(9):5344–5353View ArticleGoogle Scholar
- Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Medeiros AV, Badran A, Bonfill X et al (2013) Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 381(9869):805–816View ArticleGoogle Scholar
- Doshi RR, Fortun JA, Kim BT, Dubovy SR, Rosenfeld PJ (2014) Pseudocystic foveal cavitation in tamoxifen retinopathy. Am J Ophthalmol 157(6):1291–1298View ArticleGoogle Scholar
- Drenser K, Sarraf D, Jain A, Small KW (2006) Crystalline retinopathies. Surv Ophthalmol 51(6):535–549View ArticleGoogle Scholar
- Early Breast Cancer Trialists’ Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(9472):1687–1717View ArticleGoogle Scholar
- Kaiser-Kupfer MI, Lippman ME (1978) Tamoxifen retinopathy. Cancer Treat Rep 62(3):315–320Google Scholar
- Karamitsos A, Kokkas V, Goulas A, Paraskevopoulos P, Gougoulias K, Karampatakis V, Boboridis K (2013) Ocular surface and tear film abnormalities in women under adjuvant chemotherapy for breast cancer with the 5-fluorouracil, epirubicin and cyclophosphamide (FEC) regimen. Hippokratia 17(2):120–125Google Scholar
- Kim LA, Amarnani D, Gnanaguru G, Tseng WA, Vavvas DG, D’Amore PA (2014) Tamoxifen toxicity in cultured retinal pigment epithelial cells is mediated by concurrent regulated cell death mechanisms. Invest Ophthalmol Vis Sci 55(8):4747–4758View ArticleGoogle Scholar
- Kuchenbecker J, Pump-Schmidt C, Olbricht S, Weise W, Behrens-Baumann W (2001) Electrophysiological studies in breast carcinoma patients with tamoxifen retinopathy. Ophthalmologe 98(1):81–85View ArticleGoogle Scholar
- Li Y, Li Y, Li J, Pi G, Tan W (2014) Paclitaxel- and/or cisplatin-induced ocular neurotoxicity: a case report and literature review. Onco Targets Ther 7:1361–1366Google Scholar
- Nair AG, Das D, Goyal A, Gandhi RA (2012) The eyes have it! Tamoxifen maculopathy revisited: a case report. J Ocul Pharmacol Ther 28(6):640–642Google Scholar
- Salomao SR, Watanabe SE, Berezovsky A, Motono M (2007) Multifocal electroretinography, color discrimination and ocular toxicity in tamoxifen use. Curr Eye Res 32(4):345–352View ArticleGoogle Scholar
- Seidman AD, Barrett S, Canezo S (1994) Photopsia during 3-hour paclitaxel administration at doses> or = 250 mg/m2. J Clin Oncol 12(8):1741–1742Google Scholar
- US Food and Drug Administration, Center for Drug Evaluation and Research (2006) Nolvadex (tamoxifen citrate) NDA 017970 approval letter. AstraZeneca Group of Companies, AstraZeneca Pharmaceuticals LP Wilmington, DelawareGoogle Scholar
- Zinchuk O, Watanabe M, Hayashi N, Fukushima A, Ueno H (2006) A case of tamoxifen keratopathy. Arch Ophthalmol 124(7):1046–1048View ArticleGoogle Scholar